FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3010711580> ?p ?o ?g. }

• W3010711580 endingPage "31" @default.
• W3010711580 startingPage "21" @default.
• W3010711580 abstract "Purpose: This was an open-label phase 1a study assessing the maximum tolerated dose (MTD), safety, and tolerability of CXCR4 peptide antagonist, LY2510924, administered in combination with durvalumab in patients with advanced refractory solid tumors. Methods: Patients received LY2510924 at 20, 30, or 40 mg subcutaneous (SC) once daily in combination with durvalumab at 1500 mg intravenously (IV) on day 1 of each 28-day cycle. The primary objective was to assess the MTD and safety of LY2510924 SC daily in combination with durvalumab in patients with advanced (metastatic and/or unresectable) solid tumors. Secondary objectives included pharmacokinetics (PK) and the antitumor activity of LY2510924 in combination with durvalumab. Exploratory objectives were biomarker analysis, including pharmacodynamic markers, relevant to LY2510924 and durvalumab, including immune functioning, drug targets, cancer-related pathways, and the disease state. Results: Nine patients (three each at 20, 30, and 40 mg) were enrolled in the study (eight patients with pancreatic cancer and one patient with rectal cancer). The majority of patients completed one or two cycles (100.0% ≥ 1 cycle; 88.9% ≥ 2 cycles) of LY2510924 and durvalumab. No dose limiting toxicities were reported. Most common (>10%) treatment-emergent adverse events were injection-site reaction (44.4%), fatigue (33.3%), and increased white blood cell count (33.3%). PK parameters for combination were similar to those reported in previous studies when given as monotherapy. Best overall response of stable disease was observed in four (44.4%) patients and one patient had unconfirmed partial response. Conclusion: The recommended phase 2 dose is 40 mg SC once-daily LY2510924 in combination with durvalumab 1500 mg IV and showed acceptable safety and tolerability in patients with advanced refractory tumors." @default.
• W3010711580 created "2020-03-23" @default.
• W3010711580 creator A5008330168 @default.
• W3010711580 creator A5019501332 @default.
• W3010711580 creator A5027129499 @default.
• W3010711580 creator A5033187606 @default.
• W3010711580 creator A5034695625 @default.
• W3010711580 creator A5042029338 @default.
• W3010711580 creator A5043218456 @default.
• W3010711580 creator A5049217596 @default.
• W3010711580 creator A5058380236 @default.
• W3010711580 creator A5078259926 @default.
• W3010711580 creator A5083556285 @default.
• W3010711580 creator A5090156519 @default.
• W3010711580 date "2020-03-01" @default.
• W3010711580 modified "2023-10-15" @default.
• W3010711580 title "Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors" @default.
• W3010711580 cites W1561964696 @default.
• W3010711580 cites W1867767808 @default.
• W3010711580 cites W1930835943 @default.
• W3010711580 cites W2066671159 @default.
• W3010711580 cites W2086834665 @default.
• W3010711580 cites W2101653483 @default.
• W3010711580 cites W2102347658 @default.
• W3010711580 cites W2116018770 @default.
• W3010711580 cites W2123176392 @default.
• W3010711580 cites W2128532174 @default.
• W3010711580 cites W2135702406 @default.
• W3010711580 cites W2150048477 @default.
• W3010711580 cites W2209093312 @default.
• W3010711580 cites W2380791235 @default.
• W3010711580 cites W2560367415 @default.
• W3010711580 cites W2561193801 @default.
• W3010711580 cites W2572174216 @default.
• W3010711580 cites W2705905731 @default.
• W3010711580 cites W2745624257 @default.
• W3010711580 cites W2753065806 @default.
• W3010711580 cites W2764273516 @default.
• W3010711580 cites W2799466853 @default.
• W3010711580 doi "https://doi.org/10.1089/pancan.2019.0018" @default.
• W3010711580 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7097682" @default.
• W3010711580 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32219196" @default.
• W3010711580 hasPublicationYear "2020" @default.
• W3010711580 type Work @default.
• W3010711580 sameAs 3010711580 @default.
• W3010711580 citedByCount "25" @default.
• W3010711580 countsByYear W30107115802020 @default.
• W3010711580 countsByYear W30107115802021 @default.
• W3010711580 countsByYear W30107115802022 @default.
• W3010711580 countsByYear W30107115802023 @default.
• W3010711580 crossrefType "journal-article" @default.
• W3010711580 hasAuthorship W3010711580A5008330168 @default.
• W3010711580 hasAuthorship W3010711580A5019501332 @default.
• W3010711580 hasAuthorship W3010711580A5027129499 @default.
• W3010711580 hasAuthorship W3010711580A5033187606 @default.
• W3010711580 hasAuthorship W3010711580A5034695625 @default.
• W3010711580 hasAuthorship W3010711580A5042029338 @default.
• W3010711580 hasAuthorship W3010711580A5043218456 @default.
• W3010711580 hasAuthorship W3010711580A5049217596 @default.
• W3010711580 hasAuthorship W3010711580A5058380236 @default.
• W3010711580 hasAuthorship W3010711580A5078259926 @default.
• W3010711580 hasAuthorship W3010711580A5083556285 @default.
• W3010711580 hasAuthorship W3010711580A5090156519 @default.
• W3010711580 hasBestOaLocation W30107115801 @default.
• W3010711580 hasConcept C111113717 @default.
• W3010711580 hasConcept C112705442 @default.
• W3010711580 hasConcept C121332964 @default.
• W3010711580 hasConcept C121608353 @default.
• W3010711580 hasConcept C126322002 @default.
• W3010711580 hasConcept C142424586 @default.
• W3010711580 hasConcept C143998085 @default.
• W3010711580 hasConcept C197934379 @default.
• W3010711580 hasConcept C2776694085 @default.
• W3010711580 hasConcept C2777701055 @default.
• W3010711580 hasConcept C2777742743 @default.
• W3010711580 hasConcept C2778375690 @default.
• W3010711580 hasConcept C2779984678 @default.
• W3010711580 hasConcept C2780030458 @default.
• W3010711580 hasConcept C31760486 @default.
• W3010711580 hasConcept C71924100 @default.
• W3010711580 hasConcept C87355193 @default.
• W3010711580 hasConcept C90924648 @default.
• W3010711580 hasConcept C98274493 @default.
• W3010711580 hasConceptScore W3010711580C111113717 @default.
• W3010711580 hasConceptScore W3010711580C112705442 @default.
• W3010711580 hasConceptScore W3010711580C121332964 @default.
• W3010711580 hasConceptScore W3010711580C121608353 @default.
• W3010711580 hasConceptScore W3010711580C126322002 @default.
• W3010711580 hasConceptScore W3010711580C142424586 @default.
• W3010711580 hasConceptScore W3010711580C143998085 @default.
• W3010711580 hasConceptScore W3010711580C197934379 @default.
• W3010711580 hasConceptScore W3010711580C2776694085 @default.
• W3010711580 hasConceptScore W3010711580C2777701055 @default.
• W3010711580 hasConceptScore W3010711580C2777742743 @default.
• W3010711580 hasConceptScore W3010711580C2778375690 @default.
• W3010711580 hasConceptScore W3010711580C2779984678 @default.
• W3010711580 hasConceptScore W3010711580C2780030458 @default.
• W3010711580 hasConceptScore W3010711580C31760486 @default.

• next